EGFR and non-small cell lung carcinoma: Moreover, none of these therapies have been approved by the EMA for tumors with an amplification of MET. In this study, we described a series of patients with NSCLC with an acquired MET aberration after EGFR tyrosine kinase inhibitor (TKI) treatment and we show that crizotinib may be an effective additional therapeutic option (in addition to EGFR TKI) for the subsequent treatment of these patients.